Home
Categories
EXPLORE
True Crime
Comedy
Business
Society & Culture
History
Sports
Technology
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/a0/f3/b7/a0f3b787-bac2-8259-9747-c7e3d53fa9ca/mza_8952235022428513734.jpg/600x600bb.jpg
Few & Far Between: How Biotech Gets Built
Chris O'Brien
35 episodes
3 days ago
Welcome to Few & Far Between! Chris O'Brien, CEO of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.
Show more...
Life Sciences
Health & Fitness,
Mental Health,
Medicine,
Science
RSS
All content for Few & Far Between: How Biotech Gets Built is the property of Chris O'Brien and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Welcome to Few & Far Between! Chris O'Brien, CEO of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.
Show more...
Life Sciences
Health & Fitness,
Mental Health,
Medicine,
Science
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/a0/f3/b7/a0f3b787-bac2-8259-9747-c7e3d53fa9ca/mza_8952235022428513734.jpg/600x600bb.jpg
Episode 66: Mark Abelson, Founder of Ora Clinical
Few & Far Between: How Biotech Gets Built
43 minutes 27 seconds
3 weeks ago
Episode 66: Mark Abelson, Founder of Ora Clinical
Are clinical trial protocols a true art form? Find out in a new episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes guest Mark Ableson, founder of Ora Clinical and CRO pioneer. We'll be discussing exploratory endpoints, what to learn from failed trails, and essential factors in choosing a clinical site location. Listen today!
Few & Far Between: How Biotech Gets Built
Welcome to Few & Far Between! Chris O'Brien, CEO of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.